SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.
Manuel GrafSae Lim von StuckradAkinori UruhaJens KlotscheLydia Zorn-PaulyNadine UnterwalderThomas ButtgereitKrusche MartinChristian MeiselGerd-Rüdiger R BurmesterFalk HiepeRobert BiesenTilmann KallinichWerner StenzelUdo SchneiderThomas RosePublished in: RMD open (2022)
SIGLEC1 is a candidate biomarker to assess type I interferon activity in IIM and proved useful for monitoring disease activity and response to treatment in juvenile and adult DM.